SCHEMBL14955295

SCHEMBL14955295

Nc1c(C(=O)Nc2ccccc2C(F)(F)F)sc2nc(-c3ccncc3)ccc12

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 17/20 0.74
TP53 P04637 7/20 0.74
POLB P06746 3/20 0.74
SMN1; SMN2 Q16637 2/20 0.64
RECQL P46063 1/20 0.63
TLR9 Q9NR96 1/20 0.63
TDP1 Q9NUW8 1/20 0.62
THRB P10828 1/20 0.62
ROCK2 O75116 1/20 0.60
ROCK1 Q13464 1/20 0.60
CLK4 Q9HAZ1 1/20 0.60
MCL1 Q07820 3/20 0.56
NPC1 O15118 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
PKM P14618 1/20 0.56
RXFP1 Q9HBX9 4/20 0.54
RAB9A P51151 2/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14955198 0.86 MAPT (0.71) MAPTTP53POLBSMN1; SMN2RECQL
SCHEMBL14954689 0.85 MAPT (0.74) MAPTTP53POLBSMN1; SMN2RECQL
SCHEMBL14955454 0.85 MAPT (0.78) MAPTTP53POLBSMN1; SMN2RECQL
SCHEMBL14954720 0.83 MAPT (0.77) MAPTTP53POLBSMN1; SMN2RECQL
SCHEMBL14954959 0.83 MAPT (0.79) MAPTTP53POLBSMN1; SMN2RECQL
SCHEMBL14955704 0.83 MAPT (0.60) MAPTTP53POLBRECQLTLR9
SCHEMBL19737752 0.81 MAPT (0.85) MAPTTP53POLBSMN1; SMN2RECQL
SCHEMBL14954924 0.81 MAPT (0.71) MAPTTP53POLBSMN1; SMN2TDP1
SCHEMBL14955161 0.80 ADORA2A (0.58) MAPTTP53POLBRECQLTLR9
SCHEMBL11887884 0.79 MAPT (0.71) MAPTTP53POLBSMN1; SMN2RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2017-05-04 US disclosed
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2017-05-04 US disclosed
WO-2014089378-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2014-06-12 WO disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. (US) 2013-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130129677-A1 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections TTPA, TPMT, SLC19A2 MAPT 85/4885TP53 3393/4885POLB 4278/4885
US-20170121344-A1 THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS TTPA, TPMT, SLC19A2 MAPT 85/4885TP53 3393/4885POLB 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.